Cantor Fitzgerald Reiterates Overweight on Acumen Pharmaceuticals, Maintains $13 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $13 price target.
July 17, 2023 | 1:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Acumen Pharmaceuticals and maintained a $13 price target, indicating a positive outlook for the company.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates that the analyst believes Acumen Pharmaceuticals' stock will outperform the market in the near future. The maintained price target of $13 also suggests that the analyst sees potential for the stock's price to increase. This could have a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100